CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
On August 9, 2019, the new CTS Laboratory Information System was successfully implemented in St...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
We sincerely hope to see you at this year’s AABB Annual Meeting in Boston, MA on October 12-16...
Dr. Buff Mair is the new CTS Medical Director and replaces Dr. German Leparc who retired at the begi...
On June 13, 2019, CTS provided information regarding the manufacturer’s discontinuation of HIV...